FGFR1 and sarcoma: For example, Hasenfratz et al. (2021) presented a sarcoma arising in a GCTB in which the H3F3A mutation was lost after denosumab treatment; however, their molecular analysis of samples before and after denosumab treatment revealed an overlapping mutation for FGFR1 [18].